

VEGFR-3 fusion proteins

Alitalo, Kari Kustaa

US Patent and Trademark Office

2008-09-09

Alitalo , K K & Jeltsch , M M Sep. 09 2008 , VEGFR-3 fusion proteins , Patent No. US
7,422,741 B2 .

<http://hdl.handle.net/10138/225732>

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.



(12) **United States Patent**
Alitalo et al.

(10) **Patent No.:** **US 7,422,741 B2**
(45) **Date of Patent:** **Sep. 9, 2008**

(54) **VEGFR-3 FUSION PROTEINS**
(75) Inventors: **Kari Alitalo**, Helsinki (FI); **Markku M. Jeltsch**, Helsinki (FI)
(73) Assignee: **Vegenics Limited**, Victoria (AU)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 116 days.

5,773,289 A 6/1998 Samulski et al.
5,776,755 A 7/1998 Alitalo et al.
5,789,390 A 8/1998 Descamps et al.
5,824,544 A 10/1998 Armentano et al.
5,830,725 A 11/1998 Nolan et al.
5,830,727 A 11/1998 Wang et al.
5,834,441 A 11/1998 Philip et al.
5,849,571 A 12/1998 Glorioso et al.
5,851,521 A 12/1998 Branellec et al.
5,856,152 A 1/1999 Wilson et al.
5,863,541 A 1/1999 Samulski et al.
5,879,934 A 3/1999 DeLuca
5,888,502 A 3/1999 Guber et al.
5,952,199 A * 9/1999 Davis-Smyth et al. 435/69.7
6,011,003 A 1/2000 Charnock-Jones et al.
6,100,071 A 8/2000 Davis-Smyth et al.
6,348,333 B1 2/2002 Niwa et al.
6,375,929 B1 4/2002 Thomas, Jr. et al.
6,383,486 B1 5/2002 Davis-Smyth et al.
6,630,124 B1 10/2003 Gozes et al.
6,699,843 B2 3/2004 Pietras et al.
6,824,777 B1 11/2004 Alitalo et al.
7,034,105 B2 * 4/2006 Alitalo et al. 530/300
7,070,959 B1 7/2006 Papadopoulos et al.
2002/0103345 A1 8/2002 Zhu
2002/0162126 A1 10/2002 Beach et al.
2002/0164687 A1 11/2002 Eriksson et al.
2002/0164710 A1 11/2002 Eriksson et al.
2003/0053989 A1 3/2003 Kovessi
2003/0055006 A1 3/2003 Siemeister et al.
2003/0064053 A1 4/2003 Liu et al.
2003/0092604 A1 5/2003 Davis-Smyth et al.

(21) Appl. No.: **11/075,047**
(22) Filed: **Mar. 7, 2005**
(65) **Prior Publication Data**
US 2006/0030000 A1 Feb. 9, 2006

Related U.S. Application Data
(60) Provisional application No. 60/550,907, filed on Mar. 5, 2004.
(51) **Int. Cl.**
C07K 16/46 (2006.01)
C07K 14/705 (2006.01)
C07K 14/71 (2006.01)
C12P 21/08 (2006.01)
A61K 39/395 (2006.01)

(52) **U.S. Cl.** **424/134.1; 530/350; 530/387.3; 424/192.1**
(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

3,691,016 A 9/1972 Patel et al.
3,773,919 A 11/1973 Boswell et al.
3,969,287 A 7/1976 Jaworek et al.
4,195,128 A 3/1980 Hildebrand et al.
4,229,537 A 10/1980 Hodgins et al.
4,247,642 A 1/1981 Hirohara et al.
4,330,440 A 5/1982 Ayers et al.
4,342,776 A 8/1982 Cragoe, Jr. et al.
4,526,988 A 7/1985 Hertel
4,808,614 A 2/1989 Hertel
4,861,719 A 8/1989 Miller
5,004,758 A 4/1991 Boehm et al.
5,139,941 A 8/1992 Muzyczka et al.
5,223,608 A 6/1993 Chou et al.
5,234,784 A 8/1993 Aslam et al.
5,252,479 A 10/1993 Srivastava
5,328,688 A 7/1994 Roizman
5,474,935 A 12/1995 Chatterjee et al.
5,474,982 A 12/1995 Murray et al.
5,512,545 A 4/1996 Brown et al.
5,585,362 A 12/1996 Wilson et al.
5,620,985 A 4/1997 Jacquesy et al.
5,622,856 A 4/1997 Natsoulis
5,658,776 A 8/1997 Flotte et al.
5,661,033 A 8/1997 Ho et al.
5,670,488 A 9/1997 Gregory et al.
5,686,278 A 11/1997 Williams et al.
5,693,509 A 12/1997 Cotten et al.
5,707,618 A 1/1998 Armentano et al.
5,770,414 A 6/1998 Gage et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 418099 3/1991
WO WO-98/28621 7/1998
WO WO-00/25085 5/2000
WO WO-01/62942 8/2001
WO WO-02/060950 8/2002
WO WO-03/029814 4/2003

OTHER PUBLICATIONS

Achen et al., "Monoclonal Antibodies to Vascular Endothelial Growth Factor-D Block its Interactions with both VEGF Receptor-2 and VEGF Receptor-3," *Eur. J. Biochem.*, 267:2505-2515 (2000).
Achen et al., "Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (FLK1) and VEGF Receptor 3 (FLT4)," *Proc. Natl. Acad. Sci. (USA)*, 95(2):548-553 (1998).

(Continued)

Primary Examiner—Marianne P Allen
(74) *Attorney, Agent, or Firm*—Marshall, Gerstein & Borun LLP

(57) **ABSTRACT**

The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided.